University of California San Francisco
Give to UCSFLaura Esserman discusses breast cancer risk factors, progress in the field and the importance of tailoring treatment for women with low-risk cancer while also identifying women at high risk of invasive cancer.
UCSF's HS PROGRESS study aims to understand and treat Hidradenitis Suppurativa, an often debilitating condition disproportionately affecting women and people of color.
Diana Greene Foster, leader of a groundbreaking study on what happens to women who are denied abortions, has been named a 2023 MacArthur Fellow, one of the most coveted honors in academia, science and the arts.
Zuranolone (Zurzuvae), the first pill for patients suffering from postpartum depression, is expected to be available by the end of 2023. Though it may relieve depressive symptoms, it has some drawbacks such as sedation and dangers in breastfeeding.
Researchers have found that people who developed breast, ovary, skin and uterine cancers have significantly higher levels of endocrine-disrupting chemicals in their bodies.
The FDA recently approved the world’s first vaccines to prevent RSV for infants and elderly adults.
UCSF Medical Center has been ranked among the country’s best hospitals in adult care in U.S. News & World Report’s prestigious Best Hospitals survey.
Laws in many states require notifying women if they have dense breasts, a risk factor for breast cancer. But density shouldn’t be the only factor in determining whether supplemental screening is
UCSF researchers tested nitroglycerin patches, an treatment for chest pain from coronary artery disease, for menopausal hot flashes. Short-term benefits were seen, but not long-term as some side effects occurred.
Oncology specialists from around the globe will gather for the American Society of Clinical Oncology (ASCO) Annual Meeting to discuss the latest cancer therapies, technologies, research and education.